Amyotrophic Lateral Sclerosis (ALS)


NINDS established a National Advisory Neurological Disorders and Stroke Council (NANDSC) Working Group to identify the highest priorities for research that will lead to the discovery of effective interventions for the diagnosis, treatment, management, prevention, or cure of ALS. The strategic planning process began with a public Request for Information (RFI) that was open until February 11, 2022. RFI responses(pdf, 180 KB) are available to the public and were shared with working groups of scientists, clinicians, advocates, and people living with ALS who used this information, along with their own knowledge of the research landscape, to develop priorities for accelerating research on the biology behind ALS, translating fundamental research into potential ALS therapies, optimizing ALS clinical research, improving the quality of life for persons living with ALS through research, and identifying opportunities for collaborations and partnerships. These working groups presented their findings at ALS Strategic Priorities Workshop on October 26-27, 2022, which was free and open to the public and included opportunities for public input on the priorities.  The research priorities were posted for a 30-day public comment period and presented to the NANDSC for approval on February 1-2, 2023.

diagram of five step process for NANDS Approval

ALS Strategic Priorities

The ALS Strategic Priorities can be found at: 2023 ALS Strategic Priorities(pdf, 1658 KB).

Submitting Grant Applications

NINDS released Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS) to encourage applications to advance research activities relevant to the 2023 ALS Strategic Priorities.  We encourage researchers with ideas for grant applications that address the ALS Strategic Plan priorities to contact NIH Program Officials for ALS to help them identify the most appropriate funding opportunities and grant programs.  List of NIH Program Officials for ALS grant applications

Related Topics

Focus on Amyotrophic Lateral Sclerosis